systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-316Research ArticleСТАТЬИARTICLESМесто блокаторов рецепторов ангиотензина в лечении артериальной гипертензии согласно последним рекомендациям (2013 г.) Европейского общества по гипертонии (ESH) и Европейского общества кардиологов (ESC) по лечению артериальной гипертензииPlace of angiotensin receptor blockers in the treatment of hypertension according to the latest recommendations of the 2013 European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) for the treatment of hypertensionЧукаеваИ. И.ChukaevaI. I.chukaeva@mail.ruСоловьеваМ. В.SolovievaM. V.noemail@neicon.ruЛитвиноваС. Н.LitvinovaS. N.noemail@neicon.ruГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России, МоскваRussian Federation2013231220221042730Copyright © Чукаева И.И., Соловьева М.В., Литвинова С.Н., 20222022Чукаева И.И., Соловьева М.В., Литвинова С.Н.Chukaeva I.I., Solovieva M.V., Litvinova S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/316

В статье приведены данные последних рекомендаций (2013 г.) Европейского общества по гипертонии (ESH) и Европейского общества кардиологов (ESC) по лечению артериальной гипертензии. Особое внимание уделено группе блокаторов рецепторов ангиотензина и одному из их представителей – ирбесартану.

The following article provides the latest recommendations of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) 2013 for the treatment of hypertension. Particular attention is given to the group of angiotensin receptor blockers and irbesartan.

артериальная гипертензияблокаторы рецепторов ангиотензинаирбесартанантигипертензивная эффективностьarterial hypertensionangiotensin receptor blockersirbesartanantihypertensive efficacyReferencesЧукаева И.И. Что такое приверженность к лечению и что можно сделать для ее улучшения (на примере артериальной гипертонии). Лечебное дело. 2012; 2: 21–7.Чукаева И.И. Что такое приверженность к лечению и что можно сделать для ее улучшения (на примере артериальной гипертонии). Лечебное дело. 2012; 2: 21–7.Рекомендации Европейского общества по гипертонии (ESH) и Европейского общества кардиологов (ESC), 2013 г.Рекомендации Европейского общества по гипертонии (ESH) и Европейского общества кардиологов (ESC), 2013 г.Клиническая фармакология. Под ред. В.Г.Кукеса. 4-е изд. М.: ГЭОТАР-Медиа, 2008; с. 392–5.Клиническая фармакология. Под ред. В.Г.Кукеса. 4-е изд. М.: ГЭОТАР-Медиа, 2008; с. 392–5.Klag M.J, Whelton P.K, Randall B.L et al. End - stage renal disease in African American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293–8.Klag M.J, Whelton P.K, Randall B.L et al. End - stage renal disease in African American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293–8.Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end - stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947–53.Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end - stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947–53.De Zeeuw D, Remuzzi G, Parving H.H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7.De Zeeuw D, Remuzzi G, Parving H.H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7.Schmieder R.E, Mann J.F, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353–64.Schmieder R.E, Mann J.F, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353–64.Kunz R, Friedrich C, Wolbers M, Mann J.F. Meta - analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.Kunz R, Friedrich C, Wolbers M, Mann J.F. Meta - analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.Schmieder R.E, Hilgers K.F, Schlaich M.P, Schmidt B.M. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.Schmieder R.E, Hilgers K.F, Schlaich M.P, Schmidt B.M. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208–19.Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction inhypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.Dahlof B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction inhypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.Julius S, Kjeldsen S.E, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.Pfeffer M.A, Swedberg K, Granger C.B et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759–66.Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared with atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–9.Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces newonset atrial fibrillation and subsequent stroke compared with atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–9.Schmieder R.E, Kjeldsen S.E, Julius S et al. Reduced incidence of new - onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403–11.Schmieder R.E, Kjeldsen S.E, Julius S et al. Reduced incidence of new - onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403–11.Ong K.T, Delerme S, Pannier B et al. Aortic stiffness is reduced beyond blood pressure lowering by short - term and long - term antihypertensive treatment: a meta - analysis of individual data in 294 patients. J Hypertens 2011; 29: 1034–42.Ong K.T, Delerme S, Pannier B et al. Aortic stiffness is reduced beyond blood pressure lowering by short - term and long - term antihypertensive treatment: a meta - analysis of individual data in 294 patients. J Hypertens 2011; 29: 1034–42.Shahin Y, Khan J.A, Chetter I. Angiotensin converting enzymeinhibitors effect on arterial stiffness and wave reflections: a meta - analysis and meta - regression of randomised controlled trials. Atherosclerosis 2012; 221: 18–33.Shahin Y, Khan J.A, Chetter I. Angiotensin converting enzymeinhibitors effect on arterial stiffness and wave reflections: a meta - analysis and meta - regression of randomised controlled trials. Atherosclerosis 2012; 221: 18–33.Karalliedde J, Smith A, De Angelis L et al. Valsartan improves arterialstiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617–23.Karalliedde J, Smith A, De Angelis L et al. Valsartan improves arterialstiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51: 1617–23.Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-Converting Enzyme Inhibitorsand Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005; 46: 386–92.Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-Converting Enzyme Inhibitorsand Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005; 46: 386–92.Schrader J, Luders S, Kulschewski A et al. MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26.Schrader J, Luders S, Kulschewski A et al. MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–26.Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26: 1282–9.Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26: 1282–9.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews ofrandomised trials. Lancet 2003; 362: 1527–35.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews ofrandomised trials. Lancet 2003; 362: 1527–35.

The authors declare that there are no conflicts of interest present.